RT Journal Article
SR Electronic
T1 Intraarterial Administration Boosts <sup>177</sup>Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 406
OP 409
DO 10.2967/jnumed.121.262491
VO 63
IS 3
A1 Vonken, Evert-Jan P.A.
A1 Bruijnen, Rutger C.G.
A1 Snijders, Tom J.
A1 Seute, Tatjana
A1 Lam, Marnix G.E.H.
A1 Keizer, Bart de
A1 Braat, Arthur J.A.T.
YR 2022
UL http://jnm.snmjournals.org/content/63/3/406.abstract
AB Intravenous 177Lu-high-affinity (HA)-DOTATATE has shown promising results for the treatment of surgery- and radiotherapy-refractory meningiomas. We aimed to investigate the added value of intraarterial administration. Methods: Patients underwent at least 1 intravenous 177Lu-HA-DOTATATE treatment first and subsequent intraarterial cycles. Inpatient and intrapatient comparison was based on posttreatment 177Lu-HA-DOTATATE imaging 24 h after injection. The technical success rate and adverse events were recorded. Results: Four patients provided informed consent. The technical success rate was 100%, and no angiography-related or unexpected adverse events occurred. Intrapatient comparison showed an increased target lesion accumulation on both planar imaging (mean, +220%) and SPECT/CT (mean, +398%) after intraarterial administration, compared with intravenous administration. No unexpected adverse events occurred during follow-up. Conclusion: Intraarterial peptide receptor radionuclide therapy significantly increases tracer accumulation and is a safe and promising improvement for salvage meningioma patients. Future prospective studies on intraarterial peptide receptor radionuclide therapy are needed to determine the gain in efficacy and survival.